

Friday, October 16  
1310-1440

**Moderated ePosters 2**  
**Bladder Cancer: Various Topics I**



**MP-02.01**

RSPH9 Methylation Pattern as a Prognostic Indicator in Patients with Non-Muscle Invasive Bladder Cancer  
Yong-June Kim, South Korea

**MP-02.02**

Prospective Evaluation of Urinary Survivin Levels as a Potential Prognostic and Predictive Biomarker in Non-Muscle Invasive Bladder Cancer Cases on Intravesical BCG Therapy  
Harvinder Singh, India

**MP-02.03**

Natural Resistance-Associated Macrophage Protein 1 and Bladder Cancer Immunotherapy in Asian Patients  
Ziting Wang, Singapore

**MP-02.04**

Swedish National Register for Urinary Bladder Cancer: No Difference in Relative Survival of Bladder Cancer over Time  
Per-Uno Malmström, Sweden

**MP-02.05**

Human Serum Based Proteometabolomic Approach for Appraisal of Low- and High-Grade Bladder Cancer  
Saurabh Gupta, India

**MP-02.06**

Microscopic Hematuria Screening in a Male Consumer Population with Lower Urinary Tract Symptoms  
Claus Roehrborn, USA

**MP-02.07**

Value of NBI in the Non-Invasive Bladder Cancer Follow-Up  
Petrisor Geavlete, Romania

**MP-02.08**

An Initial Comparative Evaluation in NMIBC Endoscopic Imaging: SPIES versus NBI Technology  
Petrisor Geavlete, Romania

**MP-02.09**

En-Block Plasma-Button Resection in NMIBC Endoscopic Treatment  
Petrisor Geavlete, Romania

**MP-02.10**

The New Application of Narrow Band Imaging for Transurethral Enblock Dissection of Bladder Tumors  
Yohei Okada, Japan

**MP-02.11**

Randomized Study of One-Year Maintenance Intravesical Bacillus Calmette-Guerin Treatment for High-Risk Non-Muscle Invasive Bladder Cancer

Fuminori Sato, Japan

**MP-02.12**

Bacillus Calmette-Guerin (BCG) Intolerance Is a Significant Predictive Factor in Non-Complete Response and Progression in BCG Therapy for Non-Muscle Invasive Bladder Cancer: Evidence from a Randomized Control Trial

Akira Yokomizo, Japan

**MP-02.13**

Intravesical Bacillus Calmette-Guerin for Non-Muscle Invasive Urothelial Carcinoma of the Bladder: Patterns of Use and Impact on Outcomes

Sarah Azer, Australia